Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genes.

Prostate cancer (PCa) is one the leading causes of cancer-related deaths among men. Consequently, the identification of novel molecular targets for treatment is urgently needed to improve patients ’ outcomes. Our group recently reported that some elements of the cellular machinery controlling alternative-splicing might be useful as potential novel therapeutic tools against advanced PCa. However, the presence and functional role of RBM22, a key spliceosome component, in PCa remains unknown. Therefore, RBM22 levels were firstly interrogated in three human cohorts and two preclinical mouse models (TRAMP/Pbsn-Myc).

Source: Translational Research - September 8, 2022 Category: Research Authors: Juan M Jim énez-Vacas, Antonio J Montero-Hidalgo, Enrique Gómez-Gómez, Prudencio Sáez-Martínez, Antonio C Fuentes-Fayos, Adrià Closa, Teresa González-Serrano, Ana Martínez-López, Rafael Sánchez-Sánchez, Pedro P López-Casas, André Sarmento-Cab Source Type: research